Disselhorst Maria J, Baas Paul
Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S77-S85. doi: 10.21037/tlcr.2020.01.16.
Today there are several options for the treatment of patients with malignant pleural mesothelioma (MPM). The therapeutic arsenal has expanded from only chemotherapy with or without surgery in selected cases to a variety of new compounds that target the malignant cell or its micro-environment. Immunotherapy has been the latest achievement and now single arm and randomized studies are being presented. A renewed interest has occurred in the combination of surgery, chemotherapy and radiation therapy. In this review we present the available data on previous and running studies and try to give a recommendation how to select the best patient for the most optimal therapy.
如今，对于恶性胸膜间皮瘤（MPM）患者有多种治疗选择。治疗手段已从仅在特定病例中进行有或无手术的化疗，扩展到了多种针对恶性细胞或其微环境的新化合物。免疫疗法是最新成果，目前已有单臂研究和随机研究问世。人们对手术、化疗和放疗的联合应用重新产生了兴趣。在本综述中，我们展示了以往及正在进行的研究的现有数据，并尝试就如何为最优化治疗选择最佳患者给出建议。
